1AD
$10M4mo
Adalta
Biotechnology · Fibrosis
Clinical-stage biotech using its proprietary i-body platform (inspired by shark antibody domains) to develop therapeutics for fibrotic diseases and cancer, with lead candidate AD-214 in Phase 1 for IPF.
Cash data from Sept 2024 4C(18mo old)Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$1.9M
Sept 2024 4C
Runway
4moCRITICAL
Based on Sept 2024 4C
Market Cap
$10M
Burn Rate
$1.5M/qtr
Sept 2024 4C
Shares Outstanding
2.5B
Pipeline Assets
4
Latest Insight(1)
20 Apr 2026PartnershipAutomated cell therapy manufacturing MoU
Oribiotech Ltd and Cell Therapies Pty Ltd·co development·Asia-Pacific
3M Price
1AD.ASX$0.004-33.3% 3M
Low $0.003High $0.006
Pipeline Assets (4)
AD-214Chronic kidney disease (kidney fibrosis)
Preclinicali-PET (Granzyme B imaging)Immuno-oncology diagnostic imaging
PreclinicalAD-214Idiopathic pulmonary fibrosis (IPF)
Phase 1BZDS1901Mesothelin-positive solid tumours (mesothelioma, NSCLC, ovarian, pancreatic)
Phase 1Discovery
Preclinical
Ph 1
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
1 approved drug53 competitor trialsPhase 2+ · Non-ASX
Chronic Kidney Disease (Kidney Fibrosis)4 active trials
4 Ph2
Immuno-Oncology Diagnostic Imaging1 active trial
1 Ph1/PHASE2
Idiopathic Pulmonary Fibrosis (Ipf)48 active trials
12 Ph32 Ph2/332 Ph22 Ph1/PHASE2
Approved
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
1 paper
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Catalysts (3)
AdCella additional CAR-T in-licensing agreements
UpcomingExpectedremoveMed30 Sept 2026
AD-214 Phase 2 partner announcement / licensing deal
UpcomingSpeculativearrow_upwardHigh31 Dec 2026
BZDS1901 Australian Phase 1 initiation (AdCella)
UpcomingSpeculativearrow_upwardHigh30 June 2027
| Event | Type | Confidence | Impact | Date |
|---|
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Clinical Trials(1)
No active trials
Announcements(7)
handshake
PartnershipPSauto_awesome
Automated cell therapy manufacturing MoU20 Apr 2026
expand_more244KB